By the time this article appears, part of the destiny of the European Union for much of the next decade will be a little clearer. And that should throw some light on how European health policy will evolve in the coming years, and what sort of place medicines will be able to claim in it. Will the drug industry continue to enjoy support on patents, or suffer cutbacks in incentives? Will research grants continue to promote drug innovation, or will regulation be tightened up with a new emphasis on relative efficacy? Will medicines even retain their place in health policy, or will the focus shift increasingly toward programs of prevention and promotion? The results of May’s European Parliament (EP) elections will provide some guide to the still more influential issue of what the next European Commission is likely to do. Click Here For Complete Article Text
|
||||||||||||||||||
| Application Sequencing | ||||||||||||||||||
|
||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | |||||||||
|
|
|
|
|
|
|
|
|
|
||||||||||